{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:17:33Z","timestamp":1794590253448,"version":"4.9.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370351"],"award-info":[{"award-number":["82370351"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170355"],"award-info":[{"award-number":["82170355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.biopha.2024.116505","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T21:26:50Z","timestamp":1712179610000},"page":"116505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Canagliflozin inhibits PASMCs proliferation via regulating SGLT1\/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1101-2490","authenticated-orcid":false,"given":"Xiaojun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guili","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gufeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangbang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5544-3149","authenticated-orcid":false,"given":"Liangdi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.biopha.2024.116505_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"E.E.S.D. Group, 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.biopha.2024.116505_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.biopha.2024.116505_bib3","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.mayocp.2020.04.039","article-title":"Pulmonary hypertension: a brief guide for clinicians","volume":"95","author":"Mandras","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.biopha.2024.116505_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41569-019-0242-x","article-title":"Molecular genetic framework underlying pulmonary arterial hypertension","volume":"17","author":"Southgate","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116505_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061579","article-title":"Medical management of pulmonary arterial hypertension: current approaches and investigational drugs","volume":"15","author":"Jin","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.biopha.2024.116505_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10354","key":"10.1016\/j.biopha.2024.116505_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.biopha.2024.116505_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","article-title":"SGLT2 inhibitors: the statins of the 21st century","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur. Heart J."},{"issue":"21","key":"10.1016\/j.biopha.2024.116505_bib9","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2024.116505_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.biopha.2024.116505_bib11","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results From the EMBRACE-HF Trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.biopha.2024.116505_bib12","doi-asserted-by":"crossref","first-page":"L363","DOI":"10.1152\/ajplung.00212.2011","article-title":"The monocrotaline model of pulmonary hypertension in perspective","volume":"302","author":"Gomez-Arroyo","year":"2012","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","volume":"524","author":"Chowdhury","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2024.116505_bib14","article-title":"Dapagliflozin has no protective effect on experimental pulmonary arterial hypertension and pulmonary trunk banding rat models","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116505_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2020.01.015","article-title":"AMPK and TOR: the Yin and Yang of cellular nutrient sensing and growth control","volume":"31","author":"Gonzalez","year":"2020","journal-title":"Cell Metab."},{"issue":"18","key":"10.1016\/j.biopha.2024.116505_bib16","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2024.116505_bib17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2016.10.017","article-title":"The Na(+)-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer","volume":"170","author":"Koepsell","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2024.116505_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106049","article-title":"Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: mechanism progresses and challenges","volume":"176","author":"Li","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2024.116505_bib19","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2147\/DDDT.S418321","article-title":"SGLT1: a potential drug target for cardiovascular disease","volume":"17","author":"Zhao","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2024.116505_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.636152","article-title":"Mechanisms and perspectives of sodium-glucose co-transporter 2 inhibitors in heart failure","volume":"8","author":"Zeng","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12933-023-01816-5","article-title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms","volume":"22","author":"Huang","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"48","key":"10.1016\/j.biopha.2024.116505_bib22","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12964-021-00779-y","article-title":"Zinc-mediated activation of CREB pathway in proliferation of pulmonary artery smooth muscle cells in pulmonary hypertension","volume":"19","author":"Xiao","year":"2021","journal-title":"Cell Commun. Signal"},{"issue":"12","key":"10.1016\/j.biopha.2024.116505_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1177\/1535370218794128","article-title":"Pulmonary arterial hypertension induced by a novel method: twice-intraperitoneal injection of monocrotaline","volume":"243","author":"Zhuang","year":"2018","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"10","key":"10.1016\/j.biopha.2024.116505_bib25","first-page":"839","article-title":"Pulmonary arteriolar remodelling is prior to the increase in pulmonary arterial pressure in rats","volume":"15","author":"Lin","year":"2007","journal-title":"Chin. J. Hypertens."},{"issue":"8","key":"10.1016\/j.biopha.2024.116505_bib26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/10641963.2010.503295","article-title":"Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats","volume":"32","author":"Xie","year":"2010","journal-title":"Clin. Exp. Hypertens."},{"issue":"10","key":"10.1016\/j.biopha.2024.116505_bib27","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1080\/15384101.2023.2205209","article-title":"Zinc promotes cell proliferation via regulating metal-regulatory transcription factor 1 expression and transcriptional activity in pulmonary arterial hypertension","volume":"22","author":"Chen","year":"2023","journal-title":"Cell Cycle"},{"issue":"1-2","key":"10.1016\/j.biopha.2024.116505_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11010-018-3480-z","article-title":"CPT1 regulates the proliferation of pulmonary artery smooth muscle cells through the AMPK-p53-p21 pathway in pulmonary arterial hypertension","volume":"455","author":"Zhuang","year":"2019","journal-title":"Mol. Cell Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12890-022-02275-6","article-title":"The identification and verification of hub genes associated with pulmonary arterial hypertension using weighted gene co-expression network analysis","volume":"22","author":"Wu","year":"2022","journal-title":"BMC Pulm. Med."},{"issue":"10","key":"10.1016\/j.biopha.2024.116505_bib30","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116505_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10554-010-9596-1","article-title":"A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model","volume":"26","author":"Koskenvuo","year":"2010","journal-title":"Int. J. Cardiovasc. Imaging"},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01900-2018","article-title":"Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update","volume":"53","author":"Vonk Noordegraaf","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12890-022-01939-7","article-title":"Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension","volume":"22","author":"Tang","year":"2022","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.biopha.2024.116505_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101527","article-title":"Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1","volume":"32","author":"Behnammanesh","year":"2020","journal-title":"Redox Biol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116505_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jjcc.2022.10.003","article-title":"Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice","volume":"81","author":"Joki","year":"2023","journal-title":"J. Cardiol."},{"issue":"13","key":"10.1016\/j.biopha.2024.116505_bib36","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/cvr\/cvad119","article-title":"Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome","volume":"119","author":"Chen","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2024.116505_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109024","article-title":"SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis","volume":"110","author":"Long","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2024.116505_bib38","article-title":"SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson's disease","author":"Yu","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"10","key":"10.1016\/j.biopha.2024.116505_bib39","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J. Clin. Invest"},{"issue":"6","key":"10.1016\/j.biopha.2024.116505_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139067","article-title":"Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension","volume":"6","author":"Ntokou","year":"2021","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.biopha.2024.116505_bib41","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41401-021-00805-2","article-title":"Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress","volume":"43","author":"Ren","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12935-022-02496-z","article-title":"SGLT2 inhibition restrains thyroid cancer growth via G1\/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways","volume":"22","author":"Wang","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.biopha.2024.116505_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.biopha.2024.116505_bib44","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.116505_bib45","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10571-022-01221-8","article-title":"Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK","volume":"43","author":"Shoda","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2024.116505_bib46","article-title":"AMPK and pulmonary hypertension: crossroads between vasoconstriction and vascular remodeling","volume":"9","author":"Zhao","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116505_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116205","article-title":"AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension","volume":"23","author":"Flores","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib48","first-page":"51","article-title":"Combination treatment of adipose-derived stem cells and adiponectin attenuates pulmonary arterial hypertension in rats by inhibiting pulmonary arterial smooth muscle cell proliferation and regulating the AMPK\/BMP\/Smad pathway","volume":"41","author":"Luo","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2024.116505_bib49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.phrs.2016.03.010","article-title":"Activation of AMPK inhibits PDGF-induced pulmonary arterial smooth muscle cells proliferation and its potential mechanisms","volume":"107","author":"Song","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.116505_bib50","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1007\/s11033-014-3272-9","article-title":"Regulatory effect of AMP-activated protein kinase on pulmonary hypertension induced by chronic hypoxia in rats: in vivo and in vitro studies","volume":"41","author":"Huang","year":"2014","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2024.116505_bib51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/HYPERTENSIONAHA.116.07353","article-title":"Metformin reverses development of pulmonary hypertension via aromatase inhibition","volume":"68","author":"Dean","year":"2016","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.biopha.2024.116505_bib52","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1476-5381.2009.00445.x","article-title":"Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension","volume":"158","author":"Agard","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116505_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175579","article-title":"AMPK activation by metformin protects against pulmonary hypertension in rats and relaxes isolated human pulmonary artery","volume":"946","author":"Abdelazeem","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116505_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2024.116505_bib55","doi-asserted-by":"crossref","first-page":"1009025","DOI":"10.3389\/fphar.2022.1009025","article-title":"Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116505_bib56","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2024.116505_bib57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2020.09.005","article-title":"An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells","volume":"495","author":"Xie","year":"2020","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33293-2","article-title":"Empagliflozin ammeliorates high glucose induced-cardiac dysfuntion in human iPSC-derived cardiomyocytes","volume":"8","author":"Ng","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116505_bib60","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target","volume":"243","author":"Di Franco","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvp190","article-title":"SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states","volume":"84","author":"Banerjee","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2024.116505_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.700366","article-title":"SGLT1 Knockdown attenuates cardiac fibroblast activation in diabetic cardiac fibrosis","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116505_bib63","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-023-07024-9","article-title":"SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast","volume":"201","author":"Tsunokake","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2024.116505_bib64","first-page":"6103542","article-title":"Sodium-dependent glucose transporter 1 (SGLT1) Stabled by HER2 promotes breast cancer cell proliferation by activation of the PI3K\/Akt\/mTOR signaling pathway in HER2+ breast cancer","author":"Wang","year":"2020","journal-title":"Dis. Markers 2020"},{"key":"10.1016\/j.biopha.2024.116505_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110192","article-title":"CRISPR\/Cas9-mediated knockout of SGLT1 inhibits proliferation and alters metabolism of gastric cancer cells","volume":"90","author":"Shi","year":"2022","journal-title":"Cell Signal"},{"issue":"9","key":"10.1016\/j.biopha.2024.116505_bib66","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.biopha.2024.116505_bib67","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10557-020-07083-w","article-title":"Novel anti-inflammatory effects of canagliflozin involving hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells","volume":"35","author":"Uthman","year":"2021","journal-title":"Cardiovasc Drugs Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116505_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224003895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224003895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:06:41Z","timestamp":1782342401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224003895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":68,"alternative-id":["S0753332224003895"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116505","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canagliflozin inhibits PASMCs proliferation via regulating SGLT1\/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116505"}}